patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_350597 | REC_0013501 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 20 | 11.7 | 82 | male | 1 | 12 | 6.7 | 1 | pembrolizumab 200 mg q3w | 24.6 | false | MSS | 2026-03-15T05:36:00.416457+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_909247 | REC_0013502 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 3.9 | 54 | male | 0 | 27 | 7.6 | 5 | carboplatin + paclitaxel + pembrolizumab | 9.7 | true | MSS | 2026-03-15T05:36:00.416810+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_262804 | REC_0013503 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 27 | 6.5 | 65 | female | 0 | 13 | 5.2 | 1 | sotorasib 960 mg daily | 19.4 | false | MSS | 2026-03-15T05:36:00.417148+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_843066 | REC_0013504 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 15 | 8.9 | 77 | female | 2 | 8 | 3.5 | 5 | alectinib 600 mg BID | 15.4 | false | MSS | 2026-03-15T05:36:00.417448+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_238859 | REC_0013505 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 14.9 | 68 | female | 1 | 15 | 6.6 | 6 | osimertinib 80 mg daily | 15.3 | true | MSS | 2026-03-15T05:36:00.417745+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_719759 | REC_0013506 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 19 | 6 | 59 | female | 0 | 2 | 6.6 | 4 | osimertinib 80 mg daily | 13.2 | true | MSS | 2026-03-15T05:36:00.418047+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_860536 | REC_0013507 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 29 | 14.4 | 74 | female | 1 | 17 | 5.5 | 4 | osimertinib 80 mg daily | 12.4 | false | MSS | 2026-03-15T05:36:00.418365+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_286282 | REC_0013508 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 18 | 13.6 | 70 | female | 1 | 14 | 7 | 0 | osimertinib 80 mg daily | 36.8 | false | MSS | 2026-03-15T05:36:00.418855+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_824267 | REC_0013509 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 13.9 | 57 | male | 1 | 8 | 5.3 | 6 | alectinib 600 mg BID | 14.8 | false | MSI-H | 2026-03-15T05:36:00.419241+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_948987 | REC_0013510 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 27 | 15.2 | 61 | male | 0 | 16 | 6.6 | 2 | entrectinib 600 mg daily | 15.7 | false | MSI-H | 2026-03-15T05:36:00.419584+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_167198 | REC_0013511 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 24 | 7.4 | 66 | female | 0 | 9 | 4.8 | 2 | sotorasib 960 mg daily | 11.5 | true | MSS | 2026-03-15T05:36:00.419945+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_221578 | REC_0013512 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 36 | 15 | 76 | female | 1 | 15 | 6 | 6 | alectinib 600 mg BID | 10.3 | false | MSS | 2026-03-15T05:36:00.420411+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_677221 | REC_0013513 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 26 | 18.6 | 69 | male | 1 | 19 | 5.8 | 2 | alectinib 600 mg BID | 18.8 | false | MSI-H | 2026-03-15T05:36:00.420828+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_346021 | REC_0013514 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 7.4 | 51 | female | 0 | 22 | 6.7 | 6 | entrectinib 600 mg daily | 13.8 | true | MSS | 2026-03-15T05:36:00.421234+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_517624 | REC_0013515 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 5.8 | 82 | female | 2 | 17 | 5 | 6 | osimertinib 80 mg daily | 7.6 | false | MSS | 2026-03-15T05:36:00.421610+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_988684 | REC_0013516 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 25 | 10.9 | 53 | female | 0 | 15 | 4.3 | 2 | sotorasib 960 mg daily | 5.8 | false | MSI-H | 2026-03-15T05:36:00.422004+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_738351 | REC_0013517 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 24 | 13.8 | 64 | male | 0 | 18 | 6.9 | 1 | entrectinib 600 mg daily | 6 | false | MSS | 2026-03-15T05:36:00.422402+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_928167 | REC_0013518 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 9.8 | 73 | female | 2 | 17 | 4.8 | 5 | alectinib 600 mg BID | 6.8 | false | MSS | 2026-03-15T05:36:00.422780+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_317065 | REC_0013519 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 32 | 4.3 | 60 | female | 1 | 33 | 3.7 | 8 | carboplatin + paclitaxel + pembrolizumab | 13.9 | false | MSS | 2026-03-15T05:36:00.423178+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_394224 | REC_0013520 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 26 | 11.7 | 71 | female | 0 | 17 | 4 | 0 | entrectinib 600 mg daily | 38.1 | false | MSS | 2026-03-15T05:36:00.423577+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_351236 | REC_0013521 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 15.7 | 69 | female | 0 | 19 | 3.5 | 4 | sotorasib 960 mg daily | 7.2 | true | MSS | 2026-03-15T05:36:00.424223+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_578374 | REC_0013522 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 20 | 10.9 | 55 | female | 0 | 6 | 6 | 1 | osimertinib 80 mg daily | 18.3 | false | MSI-H | 2026-03-15T05:36:00.424661+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_834283 | REC_0013523 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 9.7 | 68 | female | 0 | 6 | 5.8 | 4 | entrectinib 600 mg daily | 18.6 | false | MSS | 2026-03-15T05:36:00.425020+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_502516 | REC_0013524 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 26 | 4 | 56 | female | 1 | 26 | 6.2 | 1 | carboplatin + paclitaxel + pembrolizumab | 8.3 | true | MSS | 2026-03-15T05:36:00.425378+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_689161 | REC_0013525 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 7.7 | 68 | female | 0 | 4 | 6.3 | 6 | sotorasib 960 mg daily | 10.9 | true | MSS | 2026-03-15T05:36:00.425731+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_363745 | REC_0013526 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 25 | 5.8 | 71 | female | 1 | 61 | 3.7 | 2 | carboplatin + paclitaxel + pembrolizumab | 14.8 | false | MSS | 2026-03-15T05:36:00.426078+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_716702 | REC_0013527 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 35 | 18.5 | 77 | male | 1 | 20 | 3.7 | 1 | pembrolizumab 200 mg q3w | 13.8 | false | MSS | 2026-03-15T05:36:00.426442+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_522266 | REC_0013528 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 14.8 | 55 | male | 1 | 5 | 8.2 | 5 | entrectinib 600 mg daily | 7 | false | MSI-H | 2026-03-15T05:36:00.426804+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_538954 | REC_0013529 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 11 | 16.5 | 66 | female | 1 | 16 | 3.9 | 1 | alectinib 600 mg BID | 17.4 | false | MSI-H | 2026-03-15T05:36:00.427154+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_461702 | REC_0013530 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 22 | 10.6 | 60 | female | 0 | 5 | 4.3 | 1 | entrectinib 600 mg daily | 13.7 | true | MSI-H | 2026-03-15T05:36:00.427545+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_297112 | REC_0013531 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 18 | 13.4 | 84 | female | 2 | 20 | 4.9 | 1 | alectinib 600 mg BID | 18.2 | true | MSS | 2026-03-15T05:36:00.427952+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_285103 | REC_0013532 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 25 | 11.2 | 50 | female | 0 | 19 | 3.9 | 2 | entrectinib 600 mg daily | 29.5 | true | MSS | 2026-03-15T05:36:00.428452+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_941935 | REC_0013533 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 23 | 10.1 | 60 | female | 0 | 15 | 6.1 | 0 | osimertinib 80 mg daily | 55 | true | MSS | 2026-03-15T05:36:00.428897+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_285000 | REC_0013534 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 20 | 10 | 83 | female | 2 | 18 | 4 | 6 | osimertinib 80 mg daily | 15.5 | false | MSS | 2026-03-15T05:36:00.429462+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_864717 | REC_0013535 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 28 | 7.2 | 76 | female | 0 | 53 | 5.7 | 2 | carboplatin + paclitaxel + pembrolizumab | 24.8 | true | MSS | 2026-03-15T05:36:00.429875+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_796955 | REC_0013536 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 22 | 12.2 | 71 | female | 1 | 25 | 4.3 | 1 | osimertinib 80 mg daily | 20 | false | MSS | 2026-03-15T05:36:00.430241+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_860062 | REC_0013537 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 31 | 14.5 | 58 | female | 0 | 18 | 4.7 | 2 | osimertinib 80 mg daily | 18.1 | false | MSI-H | 2026-03-15T05:36:00.430588+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_300566 | REC_0013538 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 23 | 17.6 | 54 | female | 0 | 17 | 6.1 | 2 | osimertinib 80 mg daily | 18.8 | false | MSI-H | 2026-03-15T05:36:00.430902+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_355078 | REC_0013539 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 21 | 18.3 | 79 | female | 2 | 18 | 4.5 | 2 | osimertinib 80 mg daily | 18.5 | false | MSI-H | 2026-03-15T05:36:00.431226+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_336004 | REC_0013540 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 31 | 7.5 | 69 | female | 0 | 13 | 6.1 | 5 | osimertinib 80 mg daily | 4 | false | MSS | 2026-03-15T05:36:00.431548+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_357730 | REC_0013541 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 9.1 | 87 | female | 2 | 20 | 5.7 | 3 | entrectinib 600 mg daily | 15.8 | true | MSS | 2026-03-15T05:36:00.431853+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_496998 | REC_0013542 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 29 | 10.9 | 52 | male | 0 | 18 | 7.4 | 1 | osimertinib 80 mg daily | 16.6 | true | MSS | 2026-03-15T05:36:00.432221+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_765464 | REC_0013543 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 16 | 9 | 60 | female | 0 | 8 | 4.6 | 6 | pembrolizumab 200 mg q3w | 6.1 | true | MSS | 2026-03-15T05:36:00.432562+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_687655 | REC_0013544 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 27 | 14.2 | 61 | female | 1 | 10 | 5.1 | 1 | sotorasib 960 mg daily | 14.9 | true | MSI-H | 2026-03-15T05:36:00.432861+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_352386 | REC_0013545 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 24 | 8.7 | 79 | male | 1 | 24 | 4 | 1 | carboplatin + paclitaxel + pembrolizumab | 30.9 | false | MSS | 2026-03-15T05:36:00.433159+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_941004 | REC_0013546 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 31 | 4.2 | 57 | male | 0 | 26 | 4.5 | 1 | carboplatin + paclitaxel + pembrolizumab | 16 | false | MSS | 2026-03-15T05:36:00.433464+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_553869 | REC_0013547 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 24 | 5 | 74 | female | 1 | 11 | 4.8 | 1 | pembrolizumab 200 mg q3w | 19.3 | true | MSS | 2026-03-15T05:36:00.433913+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_627847 | REC_0013548 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 6.5 | 60 | female | 1 | 88 | 5 | 7 | carboplatin + paclitaxel + pembrolizumab | 15.1 | false | MSS | 2026-03-15T05:36:00.434257+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_679716 | REC_0013549 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 31 | 14.4 | 80 | female | 2 | 18 | 6.5 | 3 | entrectinib 600 mg daily | 16.6 | true | MSS | 2026-03-15T05:36:00.434569+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_548999 | REC_0013550 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 18 | 17.7 | 73 | female | 2 | 13 | 5.7 | 2 | osimertinib 80 mg daily | 20.6 | false | MSS | 2026-03-15T05:36:00.434892+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_764466 | REC_0013551 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 16 | 73 | female | 1 | 8 | 4.5 | 6 | entrectinib 600 mg daily | 18 | true | MSI-H | 2026-03-15T05:36:00.435221+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_486777 | REC_0013552 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 19 | 4.8 | 67 | male | 1 | 19 | 5.8 | 4 | carboplatin + paclitaxel + pembrolizumab | 14.3 | true | MSS | 2026-03-15T05:36:00.435537+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_361806 | REC_0013553 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 16.9 | 77 | female | 2 | 20 | 4.3 | 7 | osimertinib 80 mg daily | 18.5 | true | MSI-H | 2026-03-15T05:36:00.435856+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_462433 | REC_0013554 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 29 | 8.4 | 78 | female | 1 | 17 | 5.6 | 2 | osimertinib 80 mg daily | 8 | false | MSS | 2026-03-15T05:36:00.436221+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_855718 | REC_0013555 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 12.6 | 64 | female | 1 | 22 | 5.7 | 6 | osimertinib 80 mg daily | 6.6 | true | MSS | 2026-03-15T05:36:00.436553+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_416500 | REC_0013556 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 9.8 | 65 | female | 1 | 9 | 4.9 | 10 | alectinib 600 mg BID | 9.9 | false | MSS | 2026-03-15T05:36:00.436860+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_840744 | REC_0013557 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 9.1 | 69 | female | 1 | 14 | 2.9 | 7 | osimertinib 80 mg daily | 7.2 | false | MSS | 2026-03-15T05:36:00.437148+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_162843 | REC_0013558 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 37 | 4.8 | 73 | female | 3 | 23 | 7.2 | 1 | carboplatin + paclitaxel + pembrolizumab | 23.6 | true | MSS | 2026-03-15T05:36:00.437918+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_412876 | REC_0013559 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 18 | 13.2 | 75 | female | 3 | 9 | 3.8 | 4 | osimertinib 80 mg daily | 4 | true | MSI-H | 2026-03-15T05:36:00.438301+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_255713 | REC_0013560 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 11.8 | 75 | female | 1 | 23 | 6.2 | 6 | sotorasib 960 mg daily | 15 | false | MSI-H | 2026-03-15T05:36:00.438792+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_266185 | REC_0013561 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 31 | 7.4 | 67 | female | 1 | 40 | 4.9 | 7 | carboplatin + paclitaxel + pembrolizumab | 13.9 | false | MSS | 2026-03-15T05:36:00.439145+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_237995 | REC_0013562 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 16.3 | 70 | female | 3 | 10 | 5.7 | 5 | sotorasib 960 mg daily | 10.6 | true | MSS | 2026-03-15T05:36:00.439471+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_106842 | REC_0013563 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 14.7 | 62 | female | 0 | 33 | 5.2 | 2 | alectinib 600 mg BID | 12.1 | true | MSS | 2026-03-15T05:36:00.439797+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_347685 | REC_0013564 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 6.7 | 46 | female | 0 | 1 | 5.2 | 4 | entrectinib 600 mg daily | 6.4 | true | MSS | 2026-03-15T05:36:00.440154+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_230696 | REC_0013565 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 9.8 | 60 | female | 0 | 11 | 6.4 | 5 | osimertinib 80 mg daily | 14 | true | MSS | 2026-03-15T05:36:00.440547+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_329636 | REC_0013566 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 32 | 15.7 | 69 | male | 0 | 26 | 6.1 | 5 | osimertinib 80 mg daily | 8.2 | true | MSS | 2026-03-15T05:36:00.440872+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_938503 | REC_0013567 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 27 | 20.3 | 77 | male | 2 | 13 | 6.2 | 1 | entrectinib 600 mg daily | 9.9 | true | MSS | 2026-03-15T05:36:00.441176+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_747768 | REC_0013568 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 19 | 11.3 | 76 | female | 2 | 12 | 5.2 | 2 | osimertinib 80 mg daily | 29.9 | false | MSI-H | 2026-03-15T05:36:00.441473+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_218879 | REC_0013569 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 15 | 5.2 | 58 | female | 0 | 13 | 7.2 | 6 | pembrolizumab 200 mg q3w | 7.1 | false | MSS | 2026-03-15T05:36:00.441770+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_429702 | REC_0013570 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 33 | 8.8 | 67 | female | 1 | 56 | 6.5 | 4 | carboplatin + paclitaxel + pembrolizumab | 20 | true | MSS | 2026-03-15T05:36:00.442066+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_828812 | REC_0013571 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 33 | 11.5 | 78 | male | 1 | 16 | 4.5 | 7 | alectinib 600 mg BID | 10.3 | false | MSS | 2026-03-15T05:36:00.442375+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_105808 | REC_0013572 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 24 | 7.6 | 68 | female | 1 | 11 | 5.5 | 1 | entrectinib 600 mg daily | 20.6 | false | MSS | 2026-03-15T05:36:00.442676+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_880698 | REC_0013573 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 34 | 18.8 | 66 | female | 1 | 10 | 5.8 | 1 | sotorasib 960 mg daily | 32.8 | false | MSS | 2026-03-15T05:36:00.443150+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_329511 | REC_0013574 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 25 | 12.8 | 61 | female | 0 | 18 | 4.2 | 2 | pembrolizumab 200 mg q3w | 16.6 | false | MSI-H | 2026-03-15T05:36:00.443491+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_242367 | REC_0013575 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 12.8 | 67 | female | 1 | 9 | 5.3 | 6 | osimertinib 80 mg daily | 6.5 | true | MSI-H | 2026-03-15T05:36:00.443799+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_285696 | REC_0013576 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 21 | 5.3 | 65 | male | 1 | 56 | 4.5 | 2 | carboplatin + paclitaxel + pembrolizumab | 17.8 | true | MSS | 2026-03-15T05:36:00.444144+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_748425 | REC_0013577 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 30 | 15 | 64 | female | 1 | 15 | 5.8 | 1 | entrectinib 600 mg daily | 20.8 | false | MSI-H | 2026-03-15T05:36:00.444519+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_141252 | REC_0013578 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 11.6 | 53 | male | 0 | 17 | 6.9 | 6 | osimertinib 80 mg daily | 13.2 | true | MSS | 2026-03-15T05:36:00.444846+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_972083 | REC_0013579 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 26 | 7.5 | 72 | female | 0 | 29 | 6 | 1 | carboplatin + paclitaxel + pembrolizumab | 18.2 | false | MSS | 2026-03-15T05:36:00.445162+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_227097 | REC_0013580 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 25 | 5.9 | 56 | female | 0 | 19 | 2.7 | 1 | entrectinib 600 mg daily | 19.5 | false | MSS | 2026-03-15T05:36:00.445491+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_547395 | REC_0013581 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 20 | 7.3 | 63 | female | 0 | 28 | 6.3 | 1 | carboplatin + paclitaxel + pembrolizumab | 25.4 | true | MSS | 2026-03-15T05:36:00.445820+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_165386 | REC_0013582 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 32 | 10.5 | 68 | female | 1 | 14 | 5.4 | 3 | osimertinib 80 mg daily | 10.1 | true | MSS | 2026-03-15T05:36:00.446120+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_280359 | REC_0013583 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 13.8 | 72 | female | 2 | 26 | 5.1 | 4 | osimertinib 80 mg daily | 12.7 | false | MSS | 2026-03-15T05:36:00.446423+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_583296 | REC_0013584 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 15.4 | 74 | female | 1 | 10 | 5.2 | 6 | osimertinib 80 mg daily | 10.9 | false | MSS | 2026-03-15T05:36:00.446707+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_149378 | REC_0013585 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 22 | 4.9 | 56 | female | 1 | 1 | 6.7 | 2 | osimertinib 80 mg daily | 23.5 | true | MSS | 2026-03-15T05:36:00.447043+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_244221 | REC_0013586 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 32 | 12.2 | 64 | female | 0 | 3 | 7.6 | 1 | alectinib 600 mg BID | 11.3 | false | MSS | 2026-03-15T05:36:00.447494+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_315782 | REC_0013587 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 11 | 67 | female | 0 | 21 | 5.7 | 8 | sotorasib 960 mg daily | 13.9 | true | MSS | 2026-03-15T05:36:00.447836+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_121163 | REC_0013588 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 13.6 | 74 | female | 2 | 17 | 5.3 | 4 | osimertinib 80 mg daily | 8.2 | true | MSS | 2026-03-15T05:36:00.448204+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_546957 | REC_0013589 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 27 | 7.5 | 66 | female | 0 | 7 | 7.8 | 0 | osimertinib 80 mg daily | 33.9 | false | MSS | 2026-03-15T05:36:00.448537+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_748992 | REC_0013590 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 18 | 10.5 | 79 | female | 4 | 7 | 6.2 | 7 | alectinib 600 mg BID | 14.1 | true | MSS | 2026-03-15T05:36:00.448891+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_404984 | REC_0013591 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 6.5 | 66 | female | 0 | 50 | 5.7 | 6 | carboplatin + paclitaxel + pembrolizumab | 16.1 | false | MSS | 2026-03-15T05:36:00.449252+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_533439 | REC_0013592 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 21 | 11.9 | 63 | female | 0 | 11 | 6.8 | 0 | osimertinib 80 mg daily | 36.8 | true | MSI-H | 2026-03-15T05:36:00.449604+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_381536 | REC_0013593 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 21 | 11 | 77 | female | 0 | 19 | 4.3 | 2 | alectinib 600 mg BID | 11.4 | true | MSS | 2026-03-15T05:36:00.449943+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_791168 | REC_0013594 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 28 | 6.5 | 67 | female | 1 | 53 | 4.7 | 4 | pembrolizumab 200 mg q3w | 5.6 | false | MSS | 2026-03-15T05:36:00.450278+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_802410 | REC_0013595 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 20 | 5.4 | 71 | male | 3 | 22 | 5.5 | 2 | entrectinib 600 mg daily | 19.2 | false | MSS | 2026-03-15T05:36:00.450613+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_920194 | REC_0013596 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 12.3 | 59 | male | 0 | 81 | 2.7 | 5 | carboplatin + paclitaxel + pembrolizumab | 11.3 | true | MSI-H | 2026-03-15T05:36:00.450932+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_931902 | REC_0013597 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 12 | 63 | male | 1 | 15 | 6.5 | 6 | entrectinib 600 mg daily | 15.4 | true | MSI-H | 2026-03-15T05:36:00.451222+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_768499 | REC_0013598 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 13.9 | 69 | female | 0 | 12 | 6.7 | 6 | osimertinib 80 mg daily | 10.6 | true | MSS | 2026-03-15T05:36:00.451529+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_201932 | REC_0013599 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 22 | 8.2 | 73 | male | 2 | 7 | 6.8 | 4 | pembrolizumab 200 mg q3w | 10.8 | true | MSS | 2026-03-15T05:36:00.451994+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_219366 | REC_0013600 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 8 | 66 | female | 0 | 6 | 9.5 | 4 | entrectinib 600 mg daily | 9.7 | false | MSS | 2026-03-15T05:36:00.452462+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.